Related Experiment Video

Updated: Feb 11, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Pathological Remodeling of the Myocardium in Chronic Heart Failure: Role of PGC-1α

T G Kulikova1, O V Stepanova2, A D Voronova2

  • 1National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation, Moscow, Russia. kulikoffak@mail.ru.

Bulletin of Experimental Biology and Medicine
|April 17, 2018
PubMed

Insights

In chronic heart failure, reduced activity of the master metabolism regulator PGC-1α (coactivator-1α of receptor γ activated by peroxisome proliferator) is linked to pathological cardiac hypertrophy and fetal gene reactivation.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Metabolic Regulation

Background:

  • Chronic heart failure involves pathological cardiac hypertrophy, fetal gene program reactivation, and cardiac energy metabolism dysfunction.
  • Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a key regulator of cardiac metabolism.
  • These pathological processes in heart failure are interconnected and influenced by PGC-1α activity.

Purpose of the Study:

  • To investigate the role of PGC-1α in the context of pathological cardiac remodeling in chronic heart failure.
  • To explore the relationship between PGC-1α expression, cardiac hypertrophy, and fetal gene reactivation in heart failure models.

Main Methods:

  • Utilized animal models of chronic heart failure.
  • Assessed cardiac hypertrophy, metabolic disorders, and gene expression patterns.
  • Evaluated the expression and activity levels of PGC-1α.

Main Results:

  • Animal models of chronic heart failure exhibited pathological cardiac hypertrophy.
  • These models also showed metabolic disorders and reactivation of the fetal genetic program.
  • Low PGC-1α expression and activity were observed, correlating with these pathological changes.

Conclusions:

  • Down-regulation of PGC-1α activity is a significant feature of chronic heart failure.
  • Reduced PGC-1α function is associated with pathological cardiac hypertrophy and fetal gene reactivation.
  • PGC-1α plays a critical role in regulating cardiac metabolism and preventing pathological remodeling in heart failure.

Keywords:
PGC-1αfetal cardiomyocytesfetal genetic programmyocardial energy metabolismpathological cardiac hypertrophy

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.9K
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360